edetic acid has been researched along with gefitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beijnen, JH; Durmus, S; Schellens, JH; Schinkel, AH; Sparidans, RW | 1 |
1 review(s) available for edetic acid and gefitinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for edetic acid and gefitinib
| Article | Year |
|---|---|
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Topics: Acetonitriles; Animals; Area Under Curve; Calibration; Chromatography, Liquid; Edetic Acid; Female; Gefitinib; Indoles; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quality Control; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2014 |